A Phase 3, Multicenter, Randomized, Open Label Study of ABBV-383 Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine change in disease symptoms of ABBV-383 compared to standard available therapies in adult participants with relapsed/refractory (R/R) MM.
ABBV-383 is an investigational drug being developed for the treatment of R/R MM. This study is broken into 2 Arms; Arm A and Arm B. . In Arm A, participants will receive ABBV-383 as a monotherapy. In Arm B, participants will receive the standard available therapy (SAT) identified by the Investigator during screening, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable. Around 380 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 140 sites across the world.
In Arm A participants will receive ABBV-383 as an infusion into the vein in 28 day cycles, during the 3.5 year study duration. In Arm B, participants will receive the SAT identified by the Investigator during screening, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable, during the 3.5 year study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.

开始日期2024-04-26

申办/合作机构

AbbVie, Inc.

NCT06158854 / Recruiting临床1/2期

An Open-Label Phase 1b Study Evaluating the Safety and Efficacy of ABBV-383 in AL Amyloidosis

Immunoglobulin light chain (AL) amyloidosis is the most common form of systemic amyloidosis. AL amyloidosis has many root causes and is characterized by the overproduction of AL that are secreted by clonal bone marrow plasma cells. This is a study to determine adverse events and change in disease activity in adult participants with AL amyloidosis treated with ABBV-383.
ABBV-383 is an investigational drug being developed for the treatment of AL amyloidosis. This study in broken into 2 parts (dose escalation and safety expansion) with 5 arms. During dose escalation (arms 1-3) participants will receive 1 of 3 doses of ABBV-383 to determine the part 2 doses. After completion of the dose escalation portion of the study, the safety expansion (part 2) portion of the study will begin. Two arms (arm 4-5) will begin and participants will receive 1 of 2 doses as determined during the dose escalation portion (part 1). Around 76 adult participants with relapsed/refractory AL amyloidosis will be enrolled at approximately 20 sites across the world.
Participants will receive ABBV-383 as an infusion into the vein for up to approximately 2 year study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.

开始日期2024-04-01

申办/合作机构

AbbVie, Inc.

NCT06223516 / Not yet recruiting临床1期

A Multicenter, Phase 1b, Open-label Study of ABBV-383 Administered Subcutaneously in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine the safety and pharmacokinetics of ABBV-383 in adult participants with relapsed/refractory (R/R) MM.
ABBV-383 is an investigational drug being developed for the treatment of R/R MM. This study is broken into 3 Arms: Arm A with 2 parts and Arm B as an expansion. Participants will receive ABBV-383 as a subcutaneous (SC) injection and intravenous (IV) infusion in Arm A and SC injections of ABBV-383 in Arm B. Around 55 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 25 sites across the world
In Arm A participants will receive one of two doses of ABBV-383 as an SC injection and (IV) infusions, during the 151 week study duration. In Arm B, participants will receive the selected dose from Arm A as SC injections, during the 151 week study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.

开始日期2024-03-23

申办/合作机构

AbbVie, Inc.

100 项与 TNB-383B 相关的临床结果

登录后查看更多信息

100 项与 TNB-383B 相关的转化医学

登录后查看更多信息

100 项与 TNB-383B 相关的专利（医药）

登录后查看更多信息

项与 TNB-383B 相关的文献（医药）

2022-11-02·Cancer Discovery

ABBV-383 Demonstrates Tolerability and Efficacy in Relapsed/Refractory MM

Article

Abstract:

The T cell–engaging bispecific antibody ABBV-383 was well tolerated in relapsed/refractory multiple myeloma (RRMM).

2022-11-01·Journal of Clinical Oncology

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

Article

作者: Kumar, Shaji ; Lee, Shane ; Bueno, Orlando F. ; Yue, Susan ; Rodriguez, Cesar ; Voorhees, Peter M. ; Vij, Ravi ; Freise, Kevin J. ; D'Souza, Anita ; Talati, Chetasi ; Weisel, Katja ; Jin, Ziyi ; Polepally, Akshanth R. ; Shah, Nina ; Buelow, Ben ; Pothacamury, Rajvineeth K. ; Ross, Jeremy A.

PURPOSE:

ABBV-383, a B-cell maturation antigen × CD3 T-cell engaging bispecific antibody, has demonstrated promising results in an ongoing first-in-human phase I study (ClinicalTrials.gov identifier: NCT03933735 ) in patients with relapsed/refractory multiple myeloma (RRMM). Herein, we report safety and efficacy outcomes of this phase I dose escalation/expansion study.

METHODS:

Patients with RRMM (≥ three prior lines including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody) were eligible. ABBV-383 was administered intravenously over 1-2 hours once every 3 weeks, without any step dosing. A 3 + 3 design with backfilling for dose escalation was used (intrapatient escalation to highest safe dose permitted) followed by initiation of dose expansion.

RESULTS:

As of January 8, 2022, 124 patients (dose escalation [0.025-120 mg], n = 73; dose expansion [60 mg], n = 51) have received ABBV-383; median age was 68 years (range, 35-92 years). The most common hematologic treatment-emergent adverse events (TEAEs) were neutropenia (all grades: 37%) and anemia (29%). The most common nonhematologic TEAEs were cytokine release syndrome (57%) and fatigue (30%). Seven deaths from TEAEs were reported with all considered unrelated to study drug by the investigator. For all efficacy-evaluable patients (n = 122; all doses), the objective response rate (ORR) was 57% and very good partial response (VGPR) or better (≥ VGPR) rate was 43%. In the 60 mg dose expansion cohort (n = 49), the ORR and ≥ VGPR rates were 59% and 39%, respectively; and in the ≥ 40 mg dose escalation plus dose expansion cohorts (n = 79) were 68% and 54%, respectively.

CONCLUSION:

ABBV-383 in patients with RRMM was well tolerated with an ORR of 68% at doses ≥ 40 mg. This novel therapy's promising preliminary antitumor activity in heavily pretreated patients warrants further clinical evaluation.

2020-07-01·eJHaem

Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma

Article

作者: Leonidas, Marina ; Ndiaye, Ami ; Voorhees, Peter M. ; Rigby, Katherine ; Foureau, David M. ; Atrash, Shebli ; Buelow, Ben ; Symanowski, James T. ; Guo, Fei ; Paul, Barry A. ; Tjaden, Elise ; Bhutani, Manisha ; Robinson, Myra ; Pham, Duy ; Steuerwald, Nury ; Usmani, Saad Z.

Abstract:

TNB‐383B is a fully human BCMA‐targeting T‐cell engaging bispecific monoclonal antibody (T‐BsAb). We assessed ex vivo efficacy of this drug to mediate killing of bone marrow mononuclear cells (BMMCs) freshly isolated from 10 patients with relapsed multiple myeloma (MM). BMMC were treated ex vivo with TNB‐383B at doses ranging from 0.001‐1 μg. Plasma cell (PC) lysis, viability, BCMA expression, CTL distribution, and degranulation were assessed by flow cytometry. Cytokine response to TNB‐383B was quantified by multiplex protein assay. Dose‐dependent PC lysis was triggered in all cases by TNB‐383B at doses as low as 0.001 μg (P = .0102). Primary MM cells varied in BCMA expression. High BCMA+ PC count correlated with increased PC lysis (P = .005) and significant CTL degranulation specific to TNB‐383B treatment (P = .0153 at 1 μg). High E:T ratio in bone marrow specimens led to lower viable and higher apoptotic PC compared with low E:T ratio (P < .001). Three cytokines were significantly modulated by TNB‐383B: IL‐2/TNFα increased by ∼4 ± 3.5‐fold average (P < .005 at 1 μg) and IP10 increased by ∼50 ± 15‐fold (P < .001 at 1 μg). We conclude that TNB‐383B triggers primary PC lysis and CTL degranulation in a dose‐dependent fashion ex vivo with no T cell expansion and mild increase of CRS‐associated cytokines.

项与 TNB-383B 相关的新闻（医药）

2024-03-16

·医药魔方

双抗药物竞争格局：市场规模超80亿美元，罗氏领跑，实体瘤产品将成主力

2023年是ADC赛道如火如荼的一年，也是双抗赛道风生水起的一年。去年，全球新增4款双抗药物获批上市，越来越多布局双抗的药企开始进入收获期。与此同时，双抗药物市场规模也来到了新的高度，12款药物的全年销售额达到了83亿美元。已上市双抗药物2023年销售额（单位：亿美元）注：*收入为安进所计全球收入+安斯泰来所计日本收入总和2023年，罗氏仍然是双抗赛道的“领头羊”，两款“重磅炸弹”药物均由其孕育而出。艾美赛珠单抗（Hemlibra）仍然是目前唯一一款在血友病领域应用的双抗药物，也是助力罗氏打下双抗“江山”的关键武器。自上市以来，该产品销售额持续快速增长，2023年已爬升至46.35亿美元，为双抗市场规模贡献超一半。不过，艾美赛珠单抗的竞争对手已经出现——诺和诺德的NNC0365-3769今年有望完成III期研究并申报上市。罗氏已有应对之策，正在开发新一代双抗NXT007，其与FIX和FX形成三元复合物的能力显著优于艾美赛珠单抗。罗氏推出的另一款重磅产品——法瑞西单抗也为双抗药物市场规模增长提供了强大的推动力，一年之间销售额实现了3倍增长（26.34 vs. 6.19亿美元）。如今，罗氏正在全力探索法瑞西单抗在其它眼科疾病上的治疗潜力，未来其市场空间将进一步扩大。法瑞西单抗作为一款VEGF-A/Ang2双抗，凭借双重作用机制以及较长的半衰期赢得了临床及市场的认可，也吸引了其它玩家进入眼科双抗赛道。据医药魔方Nextpharma数据库统计，目前全球共9款临床在研眼科双抗药物（不包括已上市的法瑞西单抗），其中6款均为VEGF/Ang2双抗。临床在研眼科双抗药物2023年也是血液瘤领域迎来更加多样化的治疗选择的一年，新增的4款上市双抗产品均为血液瘤用药。在血液瘤领域，数CD3/BCMA双抗赛道竞争最为激烈，从已上市产品和后期在研药物数量即可窥见这一点。根据医药魔方Nextpharma数据库统计，目前全球共17款进入III期阶段或申请上市阶段的双抗药物（不包括双抗ADC），其中3款为CD3/BCMA双抗，分别为linvoseltamab（再生元）、TNB-383B（艾伯维）和alnuctamab（BMS）。目前，已上市双抗药物的应用方向以血液系统恶性肿瘤为主，相关产品占比高达58%（7/12）。不过，这种趋势在近两年将出现变化，在处于后期开发阶段的双抗药物中，针对实体瘤的双抗产品已成为“大多数”。后期在研双抗药物注：红色为血液瘤产品在ADC概念盛行的当下，由双抗药物衍生的双抗ADC产品亦是药企较为关注的方向。目前，全球范围内进入后期开发阶段的双抗ADC仅JSKN-003（康宁杰瑞）和BL-B01D1（百利天恒/BMS），其余产品仍处于早期阶段。这两款产品所针对的疾病有所不同，JSKN-003主要面向乳腺癌，而BL-B01D1的应用范围更广。在极度“内卷”且市场份额正在被德曲妥珠单抗吞并的HER2赛道，JSKN-003作为进度遥遥领先的一款HER2双抗ADC，可谓是其中为数不多具有差异化优势的产品。康宁杰瑞曾在2022年年报中提到，JSKN-003的对手是德曲妥珠单抗，已有多项临床前研究结果证明二者具有可比性，并且JSKN-003可以覆盖HER2高中低表达人群。JSKN-003的另一个优势在于创新偶联技术带来的更高的血清稳定性。总的来说，JSKN-003未来所面临的市场竞争还是比较激烈的，既要与德曲妥珠单抗交战，又要与HER2双抗产品厮杀。BL-B01D1是百利天恒开发的一款HER3/EGFR双抗ADC，其小分子毒素部分为百利天恒自主研发的喜树碱衍生物ED04，DAR值为8。BL-B01D1的优势在于，其抗体部分（SI-B001）并不会直接与HER3相结合，从而避免了分子对于维持正常生理功能靶点的抑制作用，药物的毒副作用低。该产品虽是目前唯一一款HER3/EGFR双抗ADC，在同赛道尚无竞争压力。但是，来自于HER3和EGFR各自赛道的新一代在研药物也将是其不容小觑的竞争对手，例如HER3单抗ADC和四代EGFR抑制剂。在HER3赛道，全球共19款临床在研产品（包括多靶点产品），其中进度最为领先也是最为热议的莫过于第一三共的HER3单抗ADC HER3-DXd（见：全球首个！第一三共/默沙东HER3 ADC在美申报上市）。在EGFR赛道，EGFR ADC和四代EGFR抑制剂的临床进展是目前的焦点话题。EGFR ADC赛道的产品基本处于早期阶段，进度最快的MRG003（III期阶段）尚无NSCLC数据公布，未来这类产品的情况值得关注；四代EGFR抑制剂赛道，已有3款产品披露过临床数据。BBT-176（Bridge Biotherapeutics）和BLU-945（Blueprint Medicines）的数据一言难尽，但BDTX-1535倒是表现不错，ORR达到了50%（6/12）。双抗赛道和ADC赛道的发展趋势，既有所同，也有所不同。相同之处在于，这两个赛道均存在领跑企业，不同之处在于ADC赛道中的国内药企正在崛起，而双抗赛道还未形成国内药企加速进场的局面。推荐阅读制药巨头2024年展望：值得期待的里程碑事件2023年全球制药巨头自免业务排名TOP10ADC药物市场规模突破100亿美元！第一三共、罗氏、辉瑞领跑，中国药企加速进场2023年全球仿制药巨头TOP10星条旗下的宝藏：美国生物类似药市场2023概览Copyright © 2024 PHARMCUBE. All Rights Reserved.欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。精彩预告线下沙龙↑ 长按扫码，报名沙龙 ↑审核通过将收到手机短信通知

抗体药物偶联物临床3期上市批准临床2期申请上市

2024-02-22

·药时代

两款BCMA×CD3双抗报喜

正文共：1478字 3图预计阅读时间：4分钟自2009年首款双特异性抗体Catumaxomab（卡妥索单抗）获EMA批准上市之后，双抗药物研发热度持续高涨。据统计，截止2023年8月，全球共有12款双抗药物获批上市（卡妥索单抗因商业化原因于2017年退市），其中75%的药物上市时间集中在2022至2023年间。至此，双抗的收获期还在持续——两日两款BCMA×CD3双抗报喜。2024年2月20日，强生宣布FDA已批准Tecvayli（特立妥单抗）的sBLA，用于已达到并维持完全缓解（CR）至少六个月的复发性或难治性多发性（R/R）骨髓瘤（MM）患者，给药频率减少为每两周1.5 mg/kg（Q2W）。Tecvayli作为全球首款获批上市的BCMA×CD3双抗，也是MM领域首款上市双抗，首次获批于2022年8月（EMA），同年10月获FDA批准上市，用于治疗先前接受过4线或多线治疗的R/R MM患者。患者最初的推荐剂量为 0.06 mg/kg 和 0.3 mg/kg 的递增剂量，随后每周一次 1.5 mg/kg，直至疾病进展或出现不可接受的毒性。此次，Tecvayli获批的双周剂量为符合条件的患者提供了更多选择。在强生发文的一日后（2月21日），再生元宣布FDA已经同意优先审查linvoseltamab的BLA，用于治疗既往至少接受过三次治疗的R/R MM患者。PDUFA日期为2024年8月22日。有趣的是，linvoseltamab也是一款BCMA×CD3双抗，而目前全球上市的BCMA×CD3双抗仅有强生的Tecvayli与辉瑞的Elrexfio两款。本次linvoseltamab的BLA，是基于一项I/II期关键性研究（LINKER-MM1）的数据。根据2023年12月公布的中期分析结果，中位随访时间11个月，在117例接受linvoseltamab 200mg治疗的患者中，经IRC评估的ORR为71%，46%的患者实现CR或更优疗效。老产品优化+新产品获批在即，助推了BCMA×CD3双抗玩家的研发竞速热情。目前进入临床阶段的产品还有，百济神州/安进的AMG-420、艾伯维/安进的TNB-383B、康诺亚的CM336、岸迈生物的EMB-06等。在强生2023年财报中，Darzalex（抗CD38 IgG1单克隆抗体）、Carvykti（与传奇合作的CAR-T）两款MM治疗药物表现亮眼，两者的销售额分别为97.44亿美元和5亿美元。加上Tecvayli（BCMA×CD3双抗）、2023年8月上市的Talvey（CD3×GPRC5D双抗），可见强生在不断巩固其MM高地。同时，再生元的紧随而至也成为了MM治疗药物发展的一道缩影。目前，随着蛋白酶体抑制剂（如硼替佐米、卡非佐米）；免疫调节药物（如沙利度胺、泊马度胺）；CD38单抗（如Darzalex、伊沙妥昔单抗）等新型药物的应用，极大的改善了MM患者的生存结局。至于难以避免的耐药性与复发，随着CAR-T疗法（如Abecma、Carvykti、伊基奥仑赛注射液），双抗甚至ADC的加入，R/R MM患者也将拥有更多更优的选择。根据2023版NCCN指南，本次更新首次将CAR-T治疗作为难治复发患者的治疗建议。这是MM一线治疗从传统化疗走向免疫治疗的新时代，相信总有一天MM完全治愈不再只是个梦想。参考资料：1.强生官网2.再生元官网3.FDA正式批准的首款BCMA/CD3双抗，强生公司携新药TECVAYLI强势来袭（BioMedAdv）4.综述：CAR-T和双抗治疗MM的作用机制、疗效、毒性和最佳排序（细胞基因研究圈）5.其他公开资料封面图来源：123rf版权声明/免责声明本文由药时代团队原创，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至公众号或其他平台。转载授权请通过下方联系方式联络我们。本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CCO协议使用，版权归拥有者，药时代尽力注明来源。如有任何问题，请与我们联系。衷心感谢!药时代官方网站:www.drugtimes.cn联系方式:电话:13651980212微信:27674131邮箱:contact@drugtimes.cn7000亿产值从哪来？上海与生物医药如何“双向选择”阿斯利康的下个目标，能否实现？6年1.8万名受试者参与的10亿美元豪赌：失败了也值得尊敬点击这里，欣赏更多精彩内容！

财报优先审批上市批准申请上市

2024-02-21

·Firstwordpharma

FDA priority review moves Regeneron closer to myeloma nod for BCMA-targeting bispecific

The FDA has granted Regeneron Pharmaceuticals' bispecific antibody linvoseltamab a priority review to treat fourth-line patients with relapsed/refractory multiple myeloma (MM). However, while early studies suggest the BCMAxCD3 antibody may be effective, doubts remain about its ability to stand out in an increasingly crowded field of treatment options.These include other BCMAxCD3 bispecifics already on the market such as Johnson & Johnson's Tecvayli (teclistamab-cqyv) and Pfizer's Elrexfio (elranatamab-bcmm), as well as experimental candidates like AbbVie's ABBV-383, a drug in the same class (for more, see KOL Views Q&A: Leading MM specialist discusses outlook for new bispecifics from J&J, Pfizer).Regeneron's filing is backed by data from the Phase I/II LINKER-MM1 trial showing an objective response rate of 71% among patients who got the recommended 200mg dose of linvoseltamab, including 46% who had a complete response or better. After a minimum of 24 weeks of therapy, those who achieved a very good partial response or better shifted from every two-week to every four-week dosing.All patients treated with the 200mg dose experienced an adverse event (AE), including 85% who with a Grade ≥3 AE. The most common AE was cytokine release syndrome (CRS), which was reported at 46%, with the vast majority deemed to be Grade 1 or 2 cases.Promising, but indistinguishable agents?Key opinion leaders (KOLs) interviewed for a FirstWord report agreed that early data for linvoseltamab as well as for ABBV-383 appear promising, although there seems to be little to distinguish either of these agents from each other or from Tecvayli and Elrexfio. They suggested ABBV-383, which is in Phase I testing for fourth-line MM, could hold an advantage over linvoseltamab due to a less frequent dosing schedule and subcutaneous delivery, compared with the need for intravenous infusions with Regeneron's drug.European regulators have also recently accepted linvoseltamab for review. The clinical development programme for the drug includes the confirmatory Phase III trial LINKER-MM3 trial in patients with relapse/refractory MM. The study is currently enrolling and is expected to read out in 2032.Regeneron is also testing it for earlier use, including in a Phase I/II trial in the first-line setting, a Phase II trial in high-risk smoldering MM and a Phase II trial in monoclonal gammopathy of undetermined significance. Planning for a Phase I study of linvoseltamab plus one of Regeneron's CD38xCD28 costimulatory bispecifics is also in the works.

临床1期临床2期临床3期优先审批临床结果

100 项与 TNB-383B 相关的药物交易

登录后查看更多信息

研发状态

适应症	最高研发状态	国家/地区	公司
多发性骨髓瘤	临床3期	-	AbbVie, Inc. 更多
复发性多发性骨髓瘤	临床2期	美国更多	TeneoOne, Inc. 更多
浆细胞骨髓瘤难治	临床2期	德国更多	TeneoOne, Inc. 更多
免疫球蛋白轻链淀粉样变性	临床2期	日本更多	AbbVie, Inc. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


IMS2023	临床1期	复发性多发性骨髓瘤 BCMA-positive \| CD3	-	ABBV-383	鬱積淵鹽願構選廠積廠(選繭鏇淵鏇築鬱膚齋積) = anemia (29%) 窪網膚觸觸遞鹹願築衊 (蓋顧窪糧製顧襯繭獵鹽 ) 更多	-	2023-09-26
NCT03933735 (IMS2022)	临床1期	复发性多发性骨髓瘤	124	ABBV-383	鬱鏇範願願鹽鏇築鑰壓(積蓋襯積壓襯選餘糧夢) = Among pts treated at 60mg (n=60; ESC+EXP), CRS occurred in 72% of the pts (48% G1; 22% G2; 2% G3) with the first dose, with median time to onset and resolution of 1 day (0% recurrence). Other AEs observed in >20% of all pts are fatigue (30%; G3-4, 1%), anemia (29%; G3-4, 16%), nausea (29%; G3-4, 2%), diarrhea (27%; G3-4, 2%), vomiting (24%; G3-4, 0%), and neutrophil count decreased (22%; G3-4, 19%) 製選廠獵膚衊餘廠鑰蓋 (壓網壓鏇製願構積顧鏇 ) 更多	-	2022-08-25